A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
OPEN TO ACCRUAL
II
NCT02981628
bdenardo@BrownHealth.org
